Correction: HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma

Correction: HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma

Bibliographic Details
Main Authors:	Zhipeng Li, Huaxin Zhou, Zhijia Xia, Tong Xia, Gang Du, Strohmer Dorothee Franziska, Xiaoming Li, Xiangyu Zhai, Bin Jin
Format:	Article
Language:	English
Published:	BMC 2024-02-01
Series:	Biomarker Research
Online Access:	https://doi.org/10.1186/s40364-024-00574-0

Similar Items

HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma
by: Zhipeng Li, et al.
Published: (2023-03-01)

BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma
by: Xiaolong Miao, et al.
Published: (2021-10-01)

Palbociclib-Induced Cellular Senescence Is Modulated by the mTOR Complex 1 and Autophagy
by: Angel Cayo, et al.
Published: (2023-05-01)

Overexpression of HMGA1 confers radioresistance by transactivating RAD51 in cholangiocarcinoma
by: Jianping Song, et al.
Published: (2021-10-01)

Intrahepatic cholangiocarcinoma
by: A. B. Luk’yanchenko, et al.
Published: (2016-02-01)

Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway
by: Huayuan Liu, et al.
Published: (2021-09-01)

Conversion therapy for intrahepatic cholangiocarcinoma: status and perspectives
by: FANG Cheng, XIA Yong, WANG Kui, SHEN Feng
Published: (2022-05-01)

Management of Intrahepatic Cholangiocarcinoma
by: Sudha Kodali, et al.
Published: (2021-05-01)

Asbestos and Intrahepatic Cholangiocarcinoma
by: Giovanni Brandi, et al.
Published: (2020-02-01)

Intrahepatic Cholangiocarcinoma Associated with Intrahepatic Duct Stones
by: Hoon Hur, et al.
Published: (2009-01-01)

All PI3Kinase signaling is not mTOR: Dissecting mTOR-dependent and independent signaling pathways in T cells
by: Christopher Jordan Gamper, et al.
Published: (2012-10-01)

Laparoscopic vs. open anatomical hepatectomy for intrahepatic cholangiocarcinoma: A retrospective cohort study
by: Jianlei Wang, et al.
Published: (2022-10-01)

Treatment with palbociclib and tislelizumab for CDKN2A-mutated and PD-L1-positive advanced intrahepatic cholangiocarcinoma: a case report and literature review
by: Yajun Liang, et al.
Published: (2024-01-01)

The focus clinical research in intrahepatic cholangiocarcinoma
by: Yinghui Song, et al.
Published: (2022-07-01)

JNK contributes to the tumorigenic potential of human cholangiocarcinoma cells through the mTOR pathway regulated GRP78 induction.
by: Chunhong Feng, et al.
Published: (2014-01-01)

PI3K/AKT/mTOR pathway in Angiogenesis
by: Jayashree eKarar, et al.
Published: (2011-12-01)

Diagnosis of intrahepatic cholangiocarcinoma with CEUS
by: Velardi Giancarlo Gismondo, et al.
Published: (2024-02-01)

Sarcomatoid change in intrahepatic cholangiocarcinoma
by: Albrechtsen Wewer Nicolai, et al.
Published: (2013-03-01)

Molecular Profile of Intrahepatic Cholangiocarcinoma
by: Wellington Andraus, et al.
Published: (2023-12-01)

SARCOMATOID CHANGE IN INTRAHEPATIC CHOLANGIOCARCINOMA
by: Wewer Albrechtsen, et al.
Published: (2013-01-01)

Surgical Aspects of Intrahepatic Cholangiocarcinoma
by: Amram Kupietzky, et al.
Published: (2022-12-01)

Locoregional Therapy for Intrahepatic Cholangiocarcinoma
by: Mackenzie Owen, et al.
Published: (2023-04-01)

Intrahepatic Cholangiocarcinoma with Sarcomatous Changes
by: Yoshiyuki Inoue, et al.
Published: (2012-01-01)

Recurrent Intrahepatic Cholangiocarcinoma – Review
by: Yuki Bekki, et al.
Published: (2021-10-01)

A Refractory Case of CDKN2A/B Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib
by: Fan W, et al.
Published: (2023-01-01)

Rapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway.
by: Yunyang Chen, et al.
Published: (2016-01-01)

Correction to: The focus clinical research in intrahepatic cholangiocarcinoma
by: Yinghui Song, et al.
Published: (2022-09-01)

Targeting PI3K/Akt/mTOR Signaling In Cancer
by: Camillo ePorta, et al.
Published: (2014-04-01)

PI3K/Akt/mTOR inhibitors in breast cancer
by: Joycelyn JX Lee, et al.
Published: (2015-12-01)

Isolation of cancer‐associated fibroblasts and its promotion to the progression of intrahepatic cholangiocarcinoma
by: Meng Sha, et al.
Published: (2018-09-01)

Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma
by: Chunbin Zhu, et al.
Published: (2023-08-01)

Sinomenine ester derivative inhibits glioblastoma by inducing mitochondria-dependent apoptosis and autophagy by PI3K/AKT/mTOR and AMPK/mTOR pathway
by: Xiangjin Zheng, et al.
Published: (2021-11-01)

The clinical value of regional lymphadenectomy for intrahepatic cholangiocarcinoma
by: Facai Yang, et al.
Published: (2022-01-01)

The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma
by: Oraianthi Fiste, et al.
Published: (2021-04-01)

Complex Liver Resections for Intrahepatic Cholangiocarcinoma
by: Tim Reese, et al.
Published: (2021-04-01)

Advances in surgical treatment of intrahepatic cholangiocarcinoma
by: LIU Shenyang, TANG Zhaohui, QUAN Zhiwei
Published: (2022-05-01)

Effect of age on the prognosis of intrahepatic cholangiocarcinoma
by: Jung Hun Kim, et al.
Published: (2023-01-01)

Advance in Therapeutic Targets of Intrahepatic Cholangiocarcinoma
by: LIN Jian, et al.
Published: (2021-03-01)

Intrahepatic cholangiocarcinoma arising in Caroli's disease
by: Min Hye Jang, et al.
Published: (2014-12-01)

Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma
by: Serifis N, et al.
Published: (2021-11-01)